Fennec Pharmaceuticals Inc.FRX.TO

$12.69-0.16 (-1.25%)

TSXHealthcare24:00 UTC

Company snapshot

Market Cap

$451M

Small-cap

+1477%

2016 — today

10-Year Price

+385%

2016 — today

52-Week Range

$8.10$13.88

Current $12.69· 79%

Fennec Pharmaceuticals Inc., a biopharmaceutical firm established in 1996, operates from its base in Research Triangle Park, North Carolina. The company's lead investigational compound, PEDMARK, is a sodium thiosulfate formulation currently undergoing clinical development. This product candidate is specifically engineered to protect young cancer patients from platinum-induced ototoxicity, a form of hearing loss caused by chemotherapy. Previously known as Adherex Technologies Inc., the company officially rebranded to Fennec Pharmaceuticals Inc. in September 2014.

Valuation in context

P/E ratio

-42.7

N/A

Not meaningful — company is unprofitable

P/B ratio

12.0

Above average

Pricier than usual over the last 10 years

FCF Yield

-1.7%

Historically high

Historically high relative to the last 10 years

Free · No credit card needed

Get alerted when FRX.TO is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.